Zhou Bing, Xiong Jianping
Department of Pathology, The Affiliated Jiujiang Hospital of Nanchang University, Jiujiang 332000, China.
Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
Zhongguo Fei Ai Za Zhi. 2020 Mar 20;23(3):196-203. doi: 10.3779/j.issn.1009-3419.2020.03.10. Epub 2020 Feb 27.
Non-small cell lung cancer (NSCLC), as the most common pathological type of lung cancer, has the characteristics of high malignancy and aggressiveness, and the lymph nodes and different organ metastases are prone to occur in advanced stages. In recent years, with the development of precision medicine, drug resistance and treatment failure in NSCLC metastasis sites have brought difficulties for molecular targeted therapy. And studies have confirmed that these may be related to new molecular changes after tumor metastasis. This review is to describe the state of the driving genes in the primary and metastatic sites of NSCLC, and systematically review the research progress on the consistency of the state of the driving genes between the primary and corresponding metastatic lesions, which provides a new idea for exploring the molecular targeted therapy of metastatic NSCLC.
非小细胞肺癌(NSCLC)作为肺癌最常见的病理类型,具有高恶性和侵袭性的特点,晚期易发生淋巴结及不同器官转移。近年来,随着精准医学的发展,NSCLC转移部位的耐药性和治疗失败给分子靶向治疗带来了困难。并且研究证实,这些可能与肿瘤转移后的新分子变化有关。本综述旨在描述NSCLC原发灶和转移灶中驱动基因的状态,并系统回顾原发灶与相应转移灶驱动基因状态一致性的研究进展,为探索转移性NSCLC的分子靶向治疗提供新思路。